ChartRow logo
Data provided bySource: Twelve Data
ELAN
$25.85-2.12%
as of close, Nov 17, 2026
☾ AH $25.85 -2.12%
PeersZTSVTRSRDYNBIXUTHRHLN
Share this page

ELAN financial statements

The full income statement, balance sheet, and cash-flow statement for Elanco Animal Health Incorporated (ELAN), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

5Y CAGR +7.6%5Y CAGR +7.6%YoY +11.3%
$5.1B TTM$1.3B Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Gross profit

5Y CAGR +10.1%5Y CAGR +10.1%YoY +18.6%
$2.9B TTM$720M Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m5Y n/mYoY n/m
−$147M TTM$18M Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$0.29 TTM$0.04 Q3 '26
FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating cash flow

5Y n/m5Y n/mYoY −1.4%
$614M TTM$216M Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Capital expenditure

5Y CAGR −2.4%5Y CAGR −2.4%YoY −34.8%
$206M TTM$60M Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m5Y n/mYoY +22.8%
$408M TTM$156M Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Shares (diluted)

5Y +12.5%5Y +12.5%YoY +2.0%
500.1M TTM506.5M Q3 '26
FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Every ELAN chart on Trends →

Shares outstanding (point-in-time)

2024-09 494.4M2024-12 494.6M2025-03 496.6M2025-06 496.8M2025-09 496.9M2025-12 497.2M2026-03 499.4M2026-06 499.6M2026-09 499.8M+1.1% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Revenue4.71B+6.2%4.44B+0.5%4.42B+0.1%4.41B-7.4%4.76B+45.6%
2.59B+6.4%2.44B-2.0%2.49B-0.5%2.50B-5.1%2.63B+64.1%
Cost of revenue2.12B+5.9%2.00B+3.7%1.93B+0.9%1.91B-10.3%2.13B+27.9%
Research & development368M+7.0%344M+5.2%327M+1.9%321M-13.0%369M+12.2%
Selling, general & administrative1.43B+8.8%1.31B+2.3%1.28B+1.6%1.26B-9.8%1.40B+40.7%
Restructuring156M+254.5%44.0M0.00+100.0%-7.00M-106.4%110M-29.9%
Amortization of intangibles543M+3.0%527M-3.8%548M+3.8%528M-5.0%556M+54.4%
Interest expense——277M+14.9%241M+2.1%236M+57.3%
Interest & investment income43.0M+38.7%31.0M+675.0%4.00M——
Other non-operating income——-75.0M-134.4%-32.0M-540.0%-5.00M-102.8%
Pre-tax income-224M-145.9%488M+140.8%-1.20B-1559.7%-72.0M+87.4%-571M+15.7%
Income tax8.00M-94.7%150M+316.7%36.0M+500.0%6.00M+106.8%-88.0M+14.6%
-232M-168.6%338M+127.5%-1.23B-1478.2%-78.0M+83.9%-483M+15.9%
Net income to common-232M-168.6%338M+127.5%-1.23B-1478.2%-78.0M+83.9%-483M+15.9%
-$0.47-169.1%$0.68+127.2%-$2.50-1462.5%-$0.16+83.8%-$0.99+23.8%
EPS (basic)-$0.47-169.1%$0.68+127.2%-$2.50-1462.5%-$0.16+83.8%-$0.99+23.8%
Weighted-avg shares (basic)496M+0.5%494M+0.3%492M+0.8%488M+0.2%487M+10.4%
Weighted-avg shares (diluted)496M-0.2%497M+1.0%492M+0.8%488M+0.2%487M+10.4%
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
3.46B+7.6%3.21B-5.6%3.41B+3.9%3.28B+0.2%3.27B-4.2%
Cash & equivalents545M+16.5%468M+33.0%352M+2.0%345M-45.9%638M+28.9%
Accounts receivable873M+8.4%805M-4.4%842M+5.6%797M-4.3%833M-4.5%
Inventory1.74B+10.4%1.57B-9.3%1.74B+12.8%1.54B+12.2%1.37B-13.1%
Prepaid expenses236M-17.8%287M-7.4%310M-21.3%394M+66.2%237M-7.4%
13.4B+5.9%12.6B-12.2%14.4B-7.3%15.5B-6.0%16.5B-6.9%
Property, plant & equipment1.41B+41.9%993M-3.2%1.03B+2.7%999M-5.3%1.05B-19.8%
Operating lease right-of-use116M-4.9%122M-12.9%140M-0.7%141M-12.4%161M-13.9%
Goodwill4.78B+8.3%4.41B-13.3%5.09B-15.0%5.99B-2.9%6.17B-0.9%
Intangible assets3.41B-7.4%3.68B-18.1%4.49B-7.2%4.84B-13.3%5.59B-12.5%
Other non-current assets304M-2.3%311M-8.8%341M-9.8%378M-3.1%390M+12.1%
1.60B+21.4%1.31B+6.0%1.24B-27.1%1.70B+3.3%1.65B-20.7%
Accounts payable368M+24.3%296M+9.6%270M-30.8%390M-6.3%416M-17.0%
Deferred revenue416M+25.3%332M-9.5%367M+13.3%324M+1.6%319M+8.1%
Short-term & current debt74.0M+68.2%44.0M+15.8%38.0M-90.2%388M+32.0%294M-47.0%
Current lease liability38.0M+22.6%31.0M-3.1%32.0M+3.2%31.0M-8.8%34.0M-8.1%
Other current liabilities739M+58.6%466M+13.9%409M-9.9%454M+4.8%433M-25.6%
Finance lease liability (current)16.0M0.00———
6.81B+4.5%6.52B-19.9%8.14B-0.8%8.20B-8.6%8.97B-2.7%
Long-term debt3.94B-7.8%4.28B-25.4%5.74B+5.3%5.45B-9.6%6.03B+8.1%
Non-current lease liability86.0M-6.5%92.0M-16.4%110M-0.9%111M-12.6%127M-15.9%
Operating lease liability (total)124M+0.8%123M-13.4%142M+0.0%142M-11.8%161M-14.5%
Finance lease liability (total)255M0.00———
Finance lease liability239M0.00———
Deferred tax liabilities382M-14.9%449M-20.8%567M-14.4%662M-13.5%765M-15.0%
Other non-current liabilities585M+93.7%302M-26.5%411M+79.5%229M-12.6%262M-18.6%
6.55B+7.4%6.10B-2.0%6.22B-14.6%7.29B-2.9%7.51B-11.4%
Preferred stock0.000.00—0.000.00
Common stock0.000.000.000.000.00
Additional paid-in capital8.87B+0.6%8.82B+0.5%8.78B+0.4%8.74B+0.5%8.70B+0.5%
Retained earnings-2.18B-11.9%-1.95B+14.8%-2.29B-116.5%-1.06B-8.0%-979M-105.2%
Accumulated other comprehensive income-141M+81.7%-771M-189.8%-266M+32.1%-392M-87.6%-209M-169.0%
Total equity incl. non-controlling6.55B+7.4%6.10B-2.0%6.22B-14.6%7.29B-2.9%7.51B-11.4%
Total liabilities & equity13.4B+5.9%12.6B-12.2%14.4B-7.3%15.5B-6.0%16.5B-6.9%
Common shares issued497M+0.5%494M+0.3%493M+3.9%474M+0.2%473M+0.3%
Common shares outstanding497M+0.5%494M+0.3%493M+3.9%474M+0.2%473M+0.3%
Shares outstanding (cover)497M+0.5%495M+0.3%493M+0.3%492M+3.9%473M+0.2%
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
560M+3.5%541M+99.6%271M-40.0%452M-6.4%483M+1278.0%
Depreciation & amortization680M+2.7%662M-4.6%694M+1.8%682M-4.7%716M+38.5%
Intangible amortization543M+3.0%527M-3.8%548M+3.8%528M-5.0%556M+54.4%
Share-based compensation68.0M+23.6%55.0M+19.6%46.0M-22.0%59.0M-10.6%66.0M+40.4%
Deferred income taxes-134M-19.6%-112M-40.0%-80.0M-40.4%-57.0M+61.5%-148M-29.8%
Change in inventory57.0M+229.5%-44.0M-127.5%160M-40.5%269M+1027.6%-29.0M-130.5%
Other operating activities-6.00M-300.0%3.00M-72.7%11.0M0.00-100.0%11.0M-35.3%
-279M-124.1%1.16B+785.2%-169M+5.6%-179M+66.2%-530M+88.9%
Capital expenditure276M+87.8%147M+5.0%140M-18.1%171M+7.5%159M-48.9%
Free cash flow284M-27.9%394M+200.8%131M-53.4%281M-13.3%324M+192.0%
Acquisitions0.00-100.0%41.0M+115.8%19.0M0.00-100.0%342M-93.2%
Proceeds from sale of PP&E———0.00-100.0%17.0M-76.4%
Other investing activities12.0M-14.3%14.0M+40.0%10.0M+25.0%8.00M+188.9%-9.00M+65.4%
-275M+81.6%-1.49B-1697.6%-83.0M+84.9%-549M-361.4%210M-95.8%
Long-term debt issued2.11B+501.7%350M0.00-100.0%425M-15.0%500M-89.6%
Long-term debt repaid0.000.000.000.000.00
Common stock issued0.000.000.00-100.0%425M-15.0%500M-59.0%
Common stock repurchased0.000.000.000.000.00
Dividends paid0.000.000.000.000.00
Other financing activities-2.00M+88.2%-17.0M-183.3%-6.00M+81.3%-32.0M-3.2%-31.0M-93.8%
FX effect on cash71.0M+178.0%-91.0M-658.3%-12.0M+29.4%-17.0M+45.2%-31.0M-214.8%
Net change in cash77.0M-33.6%116M+1557.1%7.00M+102.4%-293M-322.0%132M-18.0%
Interest paid206M-30.4%296M-21.9%379M+42.5%266M+20.4%221M+68.7%
Income taxes paid225M+60.7%140M+47.4%95.0M+2.2%93.0M-38.4%151M+55.7%
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap11.2B+87.8%5.99B-18.5%7.34B+26.7%5.79B-56.8%13.4B-7.2%
P/E
—17.7×———
P/S2.4×+76.8%1.3×-19.8%1.7×+31.7%1.3×-54.7%2.8×-36.3%
P/B1.7×+74.9%1.0×-17.9%1.2×+39.3%0.9×-52.0%1.8×+4.7%
P/FCF39.6×+160.6%15.2×——41.4×
Earnings yield
—5.6%———
FCF yield2.5%-61.6%6.6%——2.4%
Source filing10-K10-K10-K10-K10-K
Fiscal yearCEOTotal, as reportedActually paidOther executives, average$100 in the stock$100 in peers
FY2025Mr. Jeffrey Simmons$14.9M$37.8M$3.8M$74.00$188.00
FY2024—$14.8M$9.2M$3.4M$39.00$148.00
FY2023—$13.7M$17.3M$3M$49.00$137.00
FY2022—$12.7M−$2M$2.8M$40.00$136.00
FY2021—$12.1M$16.5M$3.2M$93.00$126.00
FY2020—$9M$9.3M$2.2M——

From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.

About this data

Source: ELAN’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all ELAN filings on SEC EDGAR → Not investment advice.